Project Details
Description
Protocol ITN095AI DESIGNATE - A T cell phenotype signature driven dose finding study with siplizumab in type 1 diabetes mellitus
| Status | Active |
|---|---|
| Effective start/end date | 2/1/22 → 1/31/25 |
Funding
- BENAROYA RESEARCH INST AT VIRGINIA MASON
- NIH Nat'l Inst of Allergy & Infect Dis
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.